Alnylam Signs CRADA With US Army to Develop RNAi-Based Antivirals

Apr 13, 2006

NEW YORK, April 13 (GenomeWeb News) - Alnylam Pharmaceuticals and the United States Army Medical Research Institute of Infectious Diseases plan to co-develop RNAi therapeutics targeting viruses, Alnylam said yesterday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Mysterious Third Group

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In the Past

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

New Bases, New Drugs

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

This Week in Science

In Science this week: reduction in bee phylogenetic diversity, and more.

Main menu